spacer
spacer

PDBsum entry 2i3c

Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Hydrolase PDB id
2i3c

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
302 a.a. *
Ligands
PO4 ×8
Metals
_ZN ×2
Waters ×36
* Residue conservation analysis
PDB id:
2i3c
Name: Hydrolase
Title: Crystal structure of an aspartoacylase from homo sapiens
Structure: Aspartoacylase. Chain: a, b. Synonym: aminoacylase-2, acy-2. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: aspa, acy2, asp. Expressed in: escherichia coli. Expression_system_taxid: 562.
Biol. unit: Dimer (from PQS)
Resolution:
2.80Å     R-factor:   0.197     R-free:   0.243
Authors: E.Bitto,G.E.Wesenberg,G.N.Phillips Jr.,J.G.Mccoy,C.A.Bingman,Center For Eukaryotic Structural Genomics (Cesg)
Key ref:
E.Bitto et al. (2007). Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A, 104, 456-461. PubMed id: 17194761 DOI: 10.1073/pnas.0607817104
Date:
17-Aug-06     Release date:   29-Aug-06    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
P45381  (ACY2_HUMAN) -  Aspartoacylase from Homo sapiens
Seq:
Struc:
313 a.a.
302 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class: E.C.3.5.1.15  - aspartoacylase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: an N-acyl-L-aspartate + H2O = a carboxylate + L-aspartate
N-acyl-L-aspartate
+ H2O
= carboxylate
+ L-aspartate
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
DOI no: 10.1073/pnas.0607817104 Proc Natl Acad Sci U S A 104:456-461 (2007)
PubMed id: 17194761  
 
 
Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.
E.Bitto, C.A.Bingman, G.E.Wesenberg, J.G.McCoy, G.N.Phillips.
 
  ABSTRACT  
 
Aspartoacylase catalyzes hydrolysis of N-acetyl-l-aspartate to aspartate and acetate in the vertebrate brain. Deficiency in this activity leads to spongiform degeneration of the white matter of the brain and is the established cause of Canavan disease, a fatal progressive leukodystrophy affecting young children. We present crystal structures of recombinant human and rat aspartoacylase refined to 2.8- and 1.8-A resolution, respectively. The structures revealed that the N-terminal domain of aspartoacylase adopts a protein fold similar to that of zinc-dependent hydrolases related to carboxypeptidases A. The catalytic site of aspartoacylase shows close structural similarity to those of carboxypeptidases despite only 10-13% sequence identity between these proteins. About 100 C-terminal residues of aspartoacylase form a globular domain with a two-stranded beta-sheet linker that wraps around the N-terminal domain. The long channel leading to the active site is formed by the interface of the N- and C-terminal domains. The C-terminal domain is positioned in a way that prevents productive binding of polypeptides in the active site. The structures revealed that residues 158-164 may undergo a conformational change that results in opening and partial closing of the channel entrance. We hypothesize that the catalytic mechanism of aspartoacylase is closely analogous to that of carboxypeptidases. We identify residues involved in zinc coordination, and propose which residues may be involved in substrate binding and catalysis. The structures also provide a structural framework necessary for understanding the deleterious effects of many missense mutations of human aspartoacylase.
 
  Selected figure(s)  
 
Figure 1.
Fig. 1. Ribbon diagrams of the rASPA monomer and dimer. (A) N-domain of rASPA is color-coded in cyan and red. C-domain is color-coded in yellow and green. Residues His-21, Gly-22, Glu-24, Asn-54, Arg-63, Asn-70, Arg-71, Phe-73, Asp-114, His-116, and Glu-178 (blue sticks) are highly conserved in the AstE-AspA family and delineate the active site. Zn^2+ is shown as a pink sphere. (B) The rASPA dimer observed in the asymmetric unit of the rASPA crystals is shown in ribbon representation. Both the N-domain (red) and C-domain (green) of the rASPA monomers are involved in formation of the dimer interface. Residues His-21, Glu-24, and His-116 (blue sticks) coordinate Zn^2+ (pink sphere).
Figure 4.
Fig. 4. Proposed mechanism of action of ASPA.
 
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
21095151 S.Zano, R.Malik, S.Szucs, R.Matalon, and R.E.Viola (2011).
Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease.
  Mol Genet Metab, 102, 176-180.  
20921362 J.M.Hsieh, K.Tsirulnikov, M.R.Sawaya, N.Magilnick, N.Abuladze, I.Kurtz, J.Abramson, and A.Pushkin (2010).
Structures of aminoacylase 3 in complex with acetylated substrates.
  Proc Natl Acad Sci U S A, 107, 17962-17967.
PDB codes: 3nfz 3nh4 3nh5 3nh8
20563610 M.H.Baslow (2010).
Evidence that the tri-cellular metabolism of N-acetylaspartate functions as the brain's "operating system": how NAA metabolism supports meaningful intercellular frequency-encoded communications.
  Amino Acids, 39, 1139-1145.  
19489729 A.Edwards (2009).
Large-scale structural biology of the human proteome.
  Annu Rev Biochem, 78, 541-568.  
19362172 K.Tsirulnikov, N.Abuladze, D.Newman, S.Ryazantsev, T.Wolak, N.Magilnick, M.C.Koag, I.Kurtz, and A.Pushkin (2009).
Mouse aminoacylase 3: a metalloenzyme activated by cobalt and nickel.
  Biochim Biophys Acta, 1794, 1049-1057.  
19319678 M.H.Baslow, and D.N.Guilfoyle (2009).
Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in canavan disease?
  Neurochem Res, 34, 1523-1534.  
20003521 R.E.Connon, J.Geist, J.Pfeiff, A.V.Loguinov, L.S.D'Abronzo, H.Wintz, C.D.Vulpe, and I.Werner (2009).
Linking mechanistic and behavioral responses to sublethal esfenvalerate exposure in the endangered delta smelt; Hypomesus transpacificus (Fam. Osmeridae).
  BMC Genomics, 10, 608.  
18293939 J.Le Coq, A.Pavlovsky, R.Malik, R.Sanishvili, C.Xu, and R.E.Viola (2008).
Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue.
  Biochemistry, 47, 3484-3492.
PDB codes: 2o4h 2o53
18282486 J.Weigelt, L.D.McBroom-Cerajewski, M.Schapira, Y.Zhao, C.H.Arrowsmith, and C.H.Arrowmsmith (2008).
Structural genomics and drug discovery: all in the family.
  Curr Opin Chem Biol, 12, 32-39.  
18978679 N.Kaya, F.Imtiaz, D.Colak, M.Al-Sayed, A.Al-Odaib, F.Al-Zahrani, B.R.Al-Mubarak, M.Al-Owain, H.Al-Dhalaan, A.Chedrawi, Z.Al-Hassnan, S.Coskun, N.Sakati, P.Ozand, and B.F.Meyer (2008).
Genome-wide gene expression profiling and mutation analysis of Saudi patients with Canavan disease.
  Genet Med, 10, 675-684.  
17786587 G.N.Phillips, B.G.Fox, J.L.Markley, B.F.Volkman, E.Bae, E.Bitto, C.A.Bingman, R.O.Frederick, J.G.McCoy, B.L.Lytle, B.S.Pierce, J.Song, and S.N.Twigger (2007).
Structures of proteins of biomedical interest from the Center for Eukaryotic Structural Genomics.
  J Struct Funct Genomics, 8, 73-84.  
17391648 J.R.Hershfield, N.Pattabiraman, C.N.Madhavarao, and M.A.Namboodiri (2007).
Mutational analysis of aspartoacylase: implications for Canavan disease.
  Brain Res, 1148, 1.  
17213329 R.E.Viola (2007).
The impact of structural biology on neurobiology.
  Proc Natl Acad Sci U S A, 104, 399-400.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.

 

spacer

spacer